Saturday 17 October 2026
Export ALUR’s income statement to Excel — free account
Allurion Technologies, Inc.
ALUR Healthcare Medical Devices
Allurion Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.2 million, down 52.6% from fiscal 2024. In the quarter to March 2026, revenue fell 47.2%, EPS fell 46.5% and free cash flow grew 66.0%, each against the same quarter a year earlier.
0.48
0.12
−20.00%
Follow ALUR
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.05 | 0.04 | 0.06 | 0.06 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.19) | (0.12) | (0.16) | (0.16) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.30 | 4.36 | 3.84 | 2.82 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.94) | (2.29) | (1.79) | (1.34) | |
EV/FCF |
(2.86) | (2.25) | (1.76) | (1.32) | |
Quick Ratio |
0.23 | 0.24 | 0.87 | 1.60 | |
Current Ratio |
0.30 | 0.33 | 1.26 | 2.02 | |
Net Debt/EBITDA |
1.42 | 0.88 | (2.79) | (2.43) | |
Debt/Assets |
0.00% | 0.00% | 177.72% | 102.13% | |
Debt/Equity |
0.00 | 0.00 | (0.39) | (0.45) | |
Asset Turnover |
0.48 | 0.63 | 0.50 | 0.53 | |
Operating CF/Net income |
0.53 | 0.88 | 0.55 | 0.82 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
30.95% | 31.30% | 75.85% | 53.27% | |
Selling, General and Administrative Expense of Revenue |
137.36% | 187.41% | 335.52% | 226.37% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
21.65% | 19.43% | 19.98% | 30.07% | |
Graham Net Nets |
(133.11) | (129.50) | (81.46) | (58.03) | |
Graham Number |
341.76 | 444.06 | 589.92 | 258.11 | |
Earnings Yield |
(8,725.28%) | (4,645.87%) | (4,710.98%) | (927.33%) | |
Free Cash Flow Yield |
(3,849.29%) | (4,774.50%) | (3,533.81%) | (3,586.14%) | |
Revenue per Share |
3.31 | 7.18 | 5.13 | 6.94 | |
Operating CF per Share |
(3.62) | (10.57) | (12.64) | (15.64) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.62) | (10.57) | (12.64) | (15.64) | |
Cash per Share |
5.68 | 10.75 | 11.85 | 26.13 | |
Shareholders Equity per Share |
(87.49) | (153.37) | (160.15) | (131.39) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(87.49) | (153.37) | (160.15) | (131.39) | |
Free Cash Flow |
(3.22) | (5.32) | (6.54) | (7.61) | |
Working Capital |
(25.95) | (25.65) | 2.98 | 11.87 | |
Net Current Asset Value |
(80.60) | (80.17) | (86.47) | (68.66) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.89 | 5.54 | 6.96 | 9.60 | |
Average Payables |
4.02 | 5.07 | 6.60 | 5.91 | |
Average Inventory |
2.71 | 3.04 | 4.12 | 4.28 | |
Average Assets |
26.20 | 24.29 | 34.42 | 37.36 | |
Average Common Equity |
(73.85) | (77.58) | (73.86) | (67.28) |
Columns are period end dates